Ankylos Implants in Turkey: Cost, Owner and Country of Origin

Search ankylos implant cost turkey and the results contain no page about Ankylos. Verified in August 2026, the top results are generic dental-implant-in-Turkey pages, because no Ankylos-specific page exists worth ranking. Search ankylos implants cost in the United Kingdom and a marketplace listing sits at the top, followed by trade price-list PDFs written for dealers. In German, where this brand has its real audience, autocomplete returns ankylos implantate preisliste and ankylos implantate katalog, again documents written for dentists rather than patients. This page is written for the patient side of that gap, and it reports specifications rather than ranking brands.

/ Where Ankylos implants are made

Ankylos is a German implant system, and both halves of that statement can be sourced separately. The origin is in the peer-reviewed record: the system's clinical concept paper comes from the Department of Oral Surgery and Implant Dentistry at the University of Frankfurt and states that the system was developed in 1985 and has been in clinical use since 1987 (PubMed 15255394). The same department later produced the largest long-term dataset for the system.

The production site is in the manufacturer's own document. The instructions for use supplied with Ankylos C/X implants carry the legal manufacturer line "Dentsply Implants Manufacturing GmbH, Rodenbacher Chaussee 4, 63457 Hanau, Germany." The same legal entity appears at the same Hanau address in the FDA establishment registration for endosseous root-form implants, and the group's fiscal 2025 annual report lists Hanau, Germany among its properties as a site manufacturing and distributing dental implant products.

A dating note matters here, because older sources give a different city. Ankylos belonged to Friadent, the German manufacturer Dentsply acquired in January 2001, and Friadent's address was Mannheim. That is why the 12,737-implant Frankfurt cohort names the manufacturer as DENTSPLY Implants Manufacturing GmbH, Mannheim, Germany (PubMed 24103113), and why the 2004 US market clearance file gives a Mannheim address. Regulatory records show the manufacturing address as Hanau from 2019 onward. Mannheim is not wrong; it is historical. The line that matters for your own implant is the manufacturer name and address printed on the implant card you receive, which our patient journey page covers.

/ Ankylos and Astra Tech sit under the same company

This connection is missing from almost every patient-facing page, and a wrong version circulates in its place: some sources file Ankylos under Nobel Biocare. That is incorrect. Ankylos is a Dentsply Sirona implant brand, and the other implant brand in that portfolio is Astra Tech. Nobel Biocare belongs to a different group entirely.

Three transactions built the present structure. Dentsply acquired Friadent GmbH, the maker of Ankylos, in January 2001; Astra Tech was acquired from AstraZeneca in 2011; the Dentsply and Sirona merger completed in February 2016. A second circulating claim can be corrected here as well: Ankylos is often said to have reached Dentsply through Degussa. The company's own annual report records the Degussa Dental acquisition as a separate transaction in October 2001, covering alloys and ceramics. Two deals in one year, routinely merged into one story.

Two practical consequences follow. First, a quote that says only "Dentsply" does not tell you which system will be placed, because the two systems in that portfolio use different connection geometries and different surface treatments. Ankylos uses the conical Morse-type TissueCare interface; the system covered on our Astra Tech page uses a different conical internal connection and a different surface. Second, component compatibility is determined at connection level rather than brand level, so sharing a parent company does not make parts interchangeable.

The same pattern exists elsewhere in the field. Three of the systems in our implant comparison table belong to a single group, covered on the Straumann, Neodent and Medentika pages, while Osstem is the brand of its own group. Knowing the group tells you nothing about quality. It tells you who you will be dealing with in ten years, which is a different and more useful question.

/ The specification sheet: grade 2 titanium and the dimensional range

The Ankylos fixture body is commercially pure titanium, grade 2. The manufacturer states the grade in more than one document: the instructions for use give titanium grade 2 to ASTM F67, the product catalogue gives grade 2 to DIN EN ISO 5832-2, and the US clearance files describe the implants as machined from commercially pure grade 2 titanium. Commercially pure titanium is unalloyed, unlike the Ti-6Al-4V alloy known as grade 5, which contains roughly 6% aluminium and 4% vanadium. Within the pure family, strength rises with oxygen and iron content: grade 2 sits around 345 MPa and grade 4 around 550 MPa, against 895 to 1200 MPa for the grade 5 alloy. Grouping all three as medical grade titanium is a common shortcut and a technically wrong one.

The dimensional envelope is documented as well. Diameters are 3.5, 4.5, 5.5 and 7.0 mm, colour-coded red, yellow, blue and green in the instructions for use, and lengths run from 6.6 to 17 mm. The shortest length carries two manufacturer restrictions that reach the patient directly: 6.6 mm implants are for two-stage protocols only, and immediate loading is not permitted at that length.

/ Product lines and the Friadent plus surface

The names that appear beside the brand on a quote are lines and components rather than separate brands. C/X denotes the current implant line and its conical connection. Balance and TitaniumBase are abutment bases used in digital workflows. SynCone is the telescopic coping system used to retain full-arch removable prostheses and is still an active line. A quote that says only Ankylos does not tell you the line, the diameter or the length, and those three are what determine both the surgical plan and the components your dentist at home will need to order.

The surface treatment is Friadent plus, described by the manufacturer as grit-blasted and high temperature-etched, with micropores reported at 0.5 to 1 micrometre. A peer-reviewed review describes the same process as large grit-blasting, etching and a proprietary neutralising step, and adds candidly that clinical data on this specific surface is limited to a few studies (PubMed 27478833). Optical interferometry classifies the surface as moderately rough with homogeneous microporosity and nanostructures of roughly 10 nm (PubMed 23823733). No roughness parameter is published by the manufacturer and no verifiable Sa value exists in the literature, so none is quoted here; the moderately rough band is defined as Sa 1.0 to 2.0 micrometres, with the caveat that differences across that band are small and often not statistically significant (PubMed 15543910). On wettability the position is unambiguous: this is a conventional surface, not a hydrophilic one.

/ What the TissueCare connection and platform switching actually do

TissueCare is the name of the interface between fixture and abutment in this system. The geometry is a conical Morse taper: the abutment seats into the fixture on a narrow-angle cone and locks by friction. The manufacturer calls it a keyed and friction-locked tapered connection with an optional index, and the instructions for use are explicit that the index is a locating aid while the conical connection provides the rotation lock and stability. All abutments share the same tapered connection regardless of size, which simplifies the restorative inventory. No cone angle in degrees appears in any manufacturer document; the 5.7 figure circulating online traces back to an abutment head diameter in millimetres and is not used here.

Platform switching is the second principle layered on top, and its definition is simple. The abutment diameter is smaller than the implant platform diameter, so the junction between fixture and abutment is drawn inward, away from the bone margin. The effect of that geometry on marginal bone has been measured independently of any brand. A current systematic review and meta-analysis reports 0.22 mm less crestal bone loss with platform switching (PubMed 40251108). A meta-analysis restricted to randomised trials with at least three years of follow-up reports mean marginal bone loss of 0.33 mm with platform switching against 0.66 mm with platform matching, while survival is effectively identical at 98.12% and 98.05% (PubMed 34698714).

The comparison worth drawing is between bone and survival. Platform switching produces a measurable bone effect and no survival effect. Network meta-analysis of randomised trials on connection geometry points the same way: conical interfaces showed less marginal bone loss and fewer prosthetic complications than external hexagonal connections, while connection design had no influence on implant survival or biological complication rates (PubMed 34776267).

/ A conical connection is not a sealed connection

Conical systems are frequently described as gap-free. That description needs a boundary drawn around it, and the manufacturer draws part of it itself: the surgical manual attributes the absence of micromovement to a chewing simulator study and states plainly that no clinical data is available on the point. The studies that measure the interface do not confirm a seal either.

An in vitro study comparing two Morse taper systems found bacterial leakage along the implant-abutment interface in 20% of assemblies in each system, with no statistically significant difference between them (PubMed 20074246). A more recent in vitro study examined three commercial systems at four tightening torques using scanning electron microscopy, and reported that the Ankylos system showed the widest microgap at every torque while also showing the lowest bacterial adherence (PubMed 38536147). Both are laboratory studies, neither reproduces intraoral conditions, and neither translates directly into a clinical outcome.

These findings are reported here for the same reason the favourable ones are. A page that reports only the flattering measurements is advertising, not a specification sheet. The defensible statement is that the conical Morse interface is a measurable design property that reduces micromovement and locks by friction, not a guarantee of a sealed junction. The clinical consequence is that the biological load at that junction is governed mainly by maintenance, which is why implant cleaning is a separate subject from implant selection.

/ Subcrestal placement: the evidence runs both ways

Subcrestal placement means positioning the implant shoulder below the level of the bone crest. It is discussed more often with this system than with most, so an honest evidence table is possible here rather than a slogan.

The general evidence first. A systematic review and meta-analysis comparing subcrestal with equicrestal placement found less marginal bone level change with subcrestal placement, but the human studies produced a difference of 0.18 mm that did not reach statistical significance, while the animal studies produced 0.45 mm that did (PubMed 29313133). Two brand-specific studies then point in different directions. A long-term retrospective study of 228 Ankylos implants found no significant difference between the two placement depths and numerically slightly more bone loss in the subcrestal group (PubMed 23675969). A retrospective study including 174 Ankylos implants found significantly more marginal bone loss below the bone level, 0.50 mm against 0.10 mm (PubMed 35235638).

The defensible summary is narrow and worth stating in that narrow form. The geometry of this system permits subcrestal placement and the published data does not show a penalty for it, but the claim that subcrestal placement preserves bone is not supported in human data. Depth is a planning decision made against bone type and soft tissue thickness, not a fixed rule, and it is settled from the CBCT scan during guided implant planning.

/ How long Ankylos implants last: three cohorts, three numbers

how long do ankylos implants last deserves three numbers rather than one, because the published record is unusually large for this brand and the figures separate by indication and cohort size.

The largest and longest cohort comes from the University of Frankfurt. Between April 1991 and May 2011, 12,737 implants were placed in 4,206 patients, and the Kaplan-Meier cumulative survival rate was 93.3% at 204 months. Most failures, 198 implants or 1.6%, occurred in the first year and before the prosthesis was delivered. Peri-implant bone loss stayed at or below 1 mm horizontally in 85.7% of implants and vertically in 85.2% at 204 months (PubMed 24103113). The second large cohort comes from a private clinic in Vienna: 18,945 implants in 7,783 patients, with cumulative survival of 98.5% at one year, 97.7% at three, 96.7% at five and 93.0% at ten (PubMed 29446204).

The third number covers a narrower indication. A Korean cohort of 450 single-tooth implants in 275 patients reported 96.9% cumulative survival at eight years, with 13 implants, or 2.9%, lost (PubMed 26813443). That is the figure most often quoted for this brand, and it is the figure behind our comparison table entry. The difference between 96.9% and 93% is not a quality gap, it is a scope gap: single-tooth restorations are a narrower indication, while the large cohorts contain every case type from full-arch work to narrow ridges. A ten-year expectation belongs in the 93% band; a single-tooth eight-year expectation belongs in the 97% band.

/ Is Ankylos a good implant: how to read that question

The query is ankylos a good implant is currently answered by a Quora thread and a dentist forum, because no sourced patient page competes for it. A sourced answer has three parts, and none of them is a ranking.

First, the size and length of the published record. Two cohorts of 12,737 and 18,945 implants place this system among the larger published datasets in implant dentistry, and both run beyond ten years. A surface characterisation study that also reviewed 56 clinical articles on this and one other system reported implant survival rates with a minimum five-year follow-up ranging between 87.7% and 100% (PubMed 23823733), which is a useful reminder of how wide the spread across individual studies is for any brand.

Second, what is missing. A PubMed search filtered to systematic reviews and meta-analyses returns no brand-specific review of Ankylos; the single record that carries the name pools five different systems (PubMed 29049323). The evidence is cohort-level, not review-level, and that should be stated rather than glossed.

Third, who produced the evidence. The largest long-term cohort comes from the university department where the system was developed, and the author of the system's clinical concept paper is among its authors (PubMed 24103113 and PubMed 15255394 share a name). That does not invalidate the data, but it is context that changes how a single-centre result should be weighted, and the strongest independent counterpart is the 18,945-implant Vienna cohort. Whether this system suits your case is decided by bone volume, site and prosthetic plan, which is what our implant comparison table is built to show.

/ Abutment neck fracture: the quantified risk in this system

Abutment fracture is the mechanical failure of the component that sits on the implant, and it can end in the loss of the implant itself. This risk has been studied more thoroughly in Ankylos than in most systems, which means it can be discussed with numbers rather than avoided.

In the single-tooth cohort, ten abutment fractures occurred across 450 implants, all located at the abutment neck, and four of them resulted in implant loss. The cumulative fracture rate was significantly higher in middle-aged patients, at molar sites and with larger-diameter implants: 0.5% at 3.5 mm diameter against 4.5% at 4.5 mm and 6.7% at 5.5 mm (PubMed 26813443). A ten-year clinical audit compared practice against the published record and reported a literature abutment fracture rate of 2.2%, an Ankylos-specific published rate of 1.8%, and its own ten-year rate of 0.6%. The same audit lists the contributing factors: male patients, first molar sites, restorations opposing a natural tooth, implants bounded by another tooth or implant, roughly six years in function before fracture, and a gonial angle below 120 degrees (PubMed 40514499).

An independent study confirms the same risk profile. Across 1,126 Ankylos implants in 430 patients followed for approximately ten years, three variables significantly predicted fracture: sex, a gonial angle below 120 degrees, and a non-splinted superstructure (PubMed 33311012). The practical response is planning rather than brand switching. If a wide-diameter single implant is planned at a molar site, splinting and a night guard belong in the conversation before surgery, alongside the standard eligibility assessment.

/ Which cases this system is used for

Neutral reporting means an indication list rather than a ranking, and the published record supports a fairly specific one.

Single-tooth replacement is the most published indication for this system, covering the 450-implant cohort and an earlier series of 275 single crowns. Full-arch fixed work has been studied as well: across 33 patients and 218 implants restored as All-on-4 and All-on-6 cases, cumulative survival beyond three years was 95.32%, with marginal bone loss of 0.27 mm mesially and 0.49 mm distally (PubMed 37248812). The general protocols are covered on our All-on-4 and All-on-6 pages, while a full-mouth restoration plan covers both arches. Loading protocol has its own dataset: 634 implants in 247 patients followed for a mean of three years under early moderate loading reported 98.74% survival (PubMed 25708235).

The decision variables are the same for every system: bone volume and density, the position of the gap, the opposing arch, occlusal load and the planned restoration. Where bone volume is insufficient the route runs through bone grafting or sinus augmentation. Where a single posterior tooth is missing, the trade-off against a bridge is set out on our implant versus bridge page and our molar implant guide. The right system is decided by the case, which is why our clinicians make that call from imaging rather than from a brand preference.

/ What determines the cost of Ankylos treatment in Turkey

ankylos implant cost turkey currently has no page behind it, and the honest version of the answer is a structure rather than a number. No figure is published here, because a price quoted before a CBCT scan describes a product rather than your treatment, and because the itemisation is what actually differs between clinics.

Five layers set the total. The fixture itself comes first: which line, which diameter and length, which abutment type. The number of stages comes second, and this is where quotes diverge most; a fixture price is not a treatment price, because a healing abutment, a definitive abutment and a restoration follow it. The restoration material is a third and separate line item, chosen independently of the implant system, and the choice between a zirconia crown and other materials moves the total on its own. Additional surgery is fourth: insufficient bone volume means grafting, and a low sinus floor in the posterior maxilla means augmentation, neither predictable without imaging. The scale of the case is fifth, and it dominates everything else once more than a few implants are involved.

Two items sit outside the quote and belong in the comparison anyway. Long-term cost covers component availability, warranty scope and the annual review schedule. Travel structure covers the number of trips and the interval between them, which for implant work is driven by healing time rather than by the clinic's schedule; our pages on how long healing takes and on dental treatment in Istanbul set out what that means in practice, and our 2026 implant pricing page explains how the itemisation is built. An itemised written quote after examination is the only version worth comparing between clinics.

/ What the Ankylos warranty actually covers

This is the section that decides your experience five years from now, and it is the one almost every page on this brand skips. Two distinct warranties are routinely merged into one. The manufacturer warranty covers the product. The clinic warranty covers workmanship, reviews and remake if required. Ask for both in writing, with duration and exclusions stated separately.

The manufacturer warranty exists as a published document and it names Ankylos. Valid as of 1 May 2023, it sets three years on instruments, five years on zirconia and lifetime cover on implants and components, with two headings of benefit: replacement at no additional charge where the product has defects in materials or workmanship, and replacement of the implant at no additional charge where osseointegration has not occurred or has failed. Four boundaries matter more than the word lifetime. The document runs in favour of eligible treating clinicians and states that patients derive no rights from it. Cover is limited to replacement of the product and explicitly excludes laboratory and clinical treatment fees. Using the product in combination with a component or instrument from another manufacturer removes the benefits. And the manufacturer reserves the right to modify or withdraw the terms without notice. The Turkish brand page repeats the lifetime claim in Turkish while linking only English documents, so a Turkish-speaking patient cannot reach the terms from the Turkish site.

/ Components and who services the implant when you fly home

Component sourcing is the question that matters most for a patient treated abroad, and this system has a specific answer with a tension inside it. The TissueCare interface is proprietary rather than a generic platform, which sounds like lock-in. In practice, compatible abutments and components for the C/X connection are catalogued by several independent manufacturers, including the Straumann Group's Medentika Y-Series, Glidewell's FDA-cleared titanium abutments, DESS, Elos Medtech and Preat, so a dentist in Germany, the Netherlands or the United Kingdom can source parts without going through a single channel. The tension is that the manufacturer's own catalogue requires C/X implants to be used only with components marked C/X, and the warranty is void once a third-party part is fitted. Third-party components carry their own warranties instead. That trade-off is a technical decision for the dentist who takes over your care, made with your documentation in front of them, not a decision to make at the point of booking.

That documentation is the part you control. European medical device law requires the manufacturer of an implantable device to supply an implant card carrying the device name, serial number, lot number, Unique Device Identification, model, and the manufacturer's name and address (Regulation (EU) 2017/745, Article 18). Leave with that card, and with the product code rather than only the brand name. A marketplace listing ranking at the top of ankylos implants cost is a reminder of why traceability matters: loose fixtures do circulate, and the card plus the packaging label peeled into your record is what distinguishes a documented implant from an undocumented one. Guidance for international patients is collected on our dental treatment in Turkey page.

/ Is Ankylos implant safe: the regulatory record

is ankylos implant safe is usually asked as a question about the brand. It is answerable as a question about public records, which is a more useful form of the same question.

In the United States, fifteen 510(k) records carry the Ankylos name, all class II under 21 CFR 872.3640 with product code DZE. Three matter for the system itself: K041509 for the Ankylos Dental Implant System, cleared 26 August 2004; K083805 for the Ankylos C/X Dental Implant System, cleared 22 May 2009; and K140347, which added the 6.6 mm length to the C/X system, cleared 20 August 2014. In Europe, the product catalogue's symbol page carries the CE mark and notified body 0123, TÜV SÜD Product Service, though that statement is written under the older medical device directive and a certificate number under the current regulation could not be located in this round.

On recalls the record is clean: no FDA recall or enforcement record is filed under the Ankylos name. A 2006 recall exists for a different implant line from the same manufacturer, which is sometimes cited as if it applied here; it does not. Adverse event reports for the brand do exist in the FDA's passive surveillance database, and they are deliberately not quoted as a rate on this page: that database has no denominator, and part of the apparent rise in report volume comes from the manufacturer unbundling summary reports into individual ones rather than from a change in device behaviour. The measurable answers to a safety question are the regulatory record and the published clinical data, both of which are set out above and on our implant treatment page.

/ Peri-implantitis and what determines the ten-year outcome

Long-term survival for this system sits in the 93% band, and the mechanism that produces the missing 7% is inflammation in the surrounding tissue rather than fatigue in the titanium. That is worth stating precisely, because it changes what a patient should optimise for.

Peri-implant disease is common. The current epidemiology review calculates weighted mean prevalences of 43% for peri-implant mucositis and 22% for peri-implantitis (PubMed 25495683). Smoking is a separate and measured variable, and this brand's own data quantifies it: in the 18,945-implant Vienna cohort, smoking was a significant factor in implant survival with a hazard ratio of 2.2 (PubMed 29446204).

Maintenance is where the measured benefit sits. A systematic review and meta-analysis of maintenance therapy found lower incidence of peri-implant disease among implants enrolled in supportive programmes and concluded that a recall interval of at least five to six months is warranted, tailored to the patient's risk profile (PubMed 26701350). The same analysis identifies a history of periodontal disease as a significant influence, which is why gum health is settled before implant planning. Our page on peri-implantitis and its modern treatment covers what happens when it does develop, and our implant-supported prosthesis page covers the restorations that sit above. Brand choice shapes the first day; maintenance shapes the tenth year, and a consultation is where the recall schedule is set.